Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879149 | 0.85 | CXCR4 (0.41) | KMT2AGAAMEN1CXCR4LMNA | |
| SCHEMBL1874610 | 0.84 | MGAM (0.42) | CXCR4TSHRCYP3A4CYP2D6L3MBTL1 | |
| SCHEMBL29823527 | 0.84 | MGAM (0.42) | CXCR4TSHRCYP3A4CYP2D6L3MBTL1 | |
| SCHEMBL1874843 | 0.82 | CXCR4 (0.39) | KMT2AGAAMEN1CXCR4LMNA | |
| SCHEMBL29823485 | 0.80 | TSHR (0.56) | KMT2AGAAMEN1TSHRLMNA | |
| SCHEMBL1875194 | 0.80 | TSHR (0.56) | KMT2AGAAMEN1TSHRLMNA | |
| SCHEMBL1886813 | 0.79 | HRH3 (0.45) | KMT2AMEN1CXCR4TSHRLMNA | |
| SCHEMBL1879072 | 0.79 | L3MBTL1 (0.39) | KMT2AGAAMEN1CXCR4TSHR | |
| SCHEMBL29823432 | 0.76 | CXCR4 (0.49) | CXCR4CYP3A4CYP2D6 | |
| SCHEMBL1877188 | 0.76 | CXCR4 (0.49) | CXCR4CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | claimed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | claimed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | ENSOMA, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | ENSOMA, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230130646-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | Magenta Therapeutics, Inc. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220401481-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4051298-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENTOR CELLS | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11260079-B2 | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells | Magenta Therapeutics, Inc. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20060193826-A1 | Methods to mobilize progenitor/stem cells | ANORMED INC. (CA) | 2006-08-31 | — | — | US | disclosed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | disclosed |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | ANORMED INC. | 2006-02-16 | — | — | US | disclosed |
| US-6987102-B2 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2006-01-17 | — | — | US | disclosed |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | ANORMED CORPORATION (CA) | 2005-02-24 | — | — | US | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | KMT2A 4150/4885GAA 4829/4885MEN1 4013/4885 |
| US-20220401481-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CSF3R, MCL1 | KMT2A 1443/4885GAA 2842/4885MEN1 243/4885 |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | CXCL12, MCL1, MYADM | KMT2A 1317/4885GAA 4122/4885MEN1 70/4885 |
| US-20230130646-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | KMT2A 1994/4885GAA 2863/4885MEN1 185/4885 |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | CXCL12, CXCR4, CXCR1 | KMT2A 1572/4885GAA 4421/4885MEN1 4770/4885 |
| US-11260079-B2 | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells | CXCL12, CD44, CD47 | KMT2A 1455/4885GAA 2677/4885MEN1 1187/4885 |
| US-20230414565-A1 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | MCL1, CXCL12, KIT | KMT2A 1864/4885GAA 1939/4885MEN1 667/4885 |
| US-20060035829-A1 | Chemokine combinations to mobilize progenitor/stem cells | CXCL12, CXCR2, CXCR4 | KMT2A 4537/4885GAA 3345/4885MEN1 4696/4885 |
| US-20060193826-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CCR2, CXCL12 | KMT2A 691/4885GAA 4674/4885MEN1 3107/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | KMT2A 1732/4885GAA 4775/4885MEN1 4046/4885 |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CXCR2 | KMT2A 1274/4885GAA 4564/4885MEN1 3350/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | KMT2A 4002/4885GAA 4834/4885MEN1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.